[Nuclear medicine diagnosis of bone metastases].
Conventional bone scintigraphy is still the standard investigation for the detection of bone metastases, especially in breast and prostate cancer. In unclear scintigraphic uptakes in the appendicular skeleton conventional x-rays are problem solving in most of the cases. In unclear uptakes in the axial skeleton additional performance of SPECT/CT can increase the specificity. Fluoride-PET/CT is superior to conventional bone scintigraphy but is not yet available in clinical routine. Patients with high-risk breast cancer and patients with lung cancer should be staged with FDG-PET/CT primarily. An additional bone scan is than superfluous. The great advantage of FDG-PET/CT is the fact that bone metastases and organ metastases can be detected in the same investigation. There is a clear trend of shifting patients from conventional nuclear medicine to PET/CT.
Strobel
K
K
Nuklearmedizin/Radiologie, Kantonsspital Luzern. klaus.strobel@ksl.ch
D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007091:Image Processing, Computer-Assisted; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D049268:Positron-Emission Tomography; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C059491:technetium Tc 99m phosphon; D019788:Fluorodeoxyglucose F18